Last Updated : May 8, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lynparza | Olaparib | Newly Diagnosed OC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | ||
| Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lokelma | sodium zirconium cyclosilicate | Hyperkalemia, adults | Do not reimburse | Complete | ||
| Soliris | eculizumab | Myasthenia Gravis (gMG), adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 8, 2024